Delirium in hospitalized patients:Implications of current evidence on clinical practice and future avenues for research-a systematic evidence review by Khan, Babar A et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delirium in hospitalized patients
Citation for published version:
Khan, BA, Zawahiri, M, Campbell, NL, Fox, GC, Weinstein, EJ, Nazir, A, Farber, MO, Buckley, JD,
Maclullich, A & Boustani, MA 2012, 'Delirium in hospitalized patients: Implications of current evidence on
clinical practice and future avenues for research-a systematic evidence review' Journal of hospital medicine
: an official publication of the Society of Hospital Medicine. DOI: 10.1002/jhm.1949
Digital Object Identifier (DOI):
10.1002/jhm.1949
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of hospital medicine : an official publication of the Society of Hospital Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Delirium in Hospitalized Patients: Implications of Current
Evidence on Clinical Practice and Future Avenues for Research
—A Systematic Evidence Review
Babar A. Khan, MD, MS1,2,3,*, Mohammed Zawahiri, MD2,3, Noll L. Campbell, PharmD,
BCPP, CGP, FASCP2,3,4,5, George C. Fox, MD, MRCPsych, Mmedsci6, Eric J. Weinstein,
MD7, Arif Nazir, MD1, Mark O. Farber, MD1, John D. Buckley, MD, MPH1, Alasdair
MacLullich, BSc, MRCP (UK), PhD8, and Malaz A. Boustani, MD, MPH1,2,3
1Indiana University School of Medicine, Indianapolis, Indiana
2Indiana University Center for Aging Research, Indianapolis, Indiana
3Regenstrief Institute, Inc, Indianapolis, Indiana
4Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette,
Indiana
5Wishard Health Services, Indianapolis, Indiana
6Dementia Research Innovation Group, Norwich School of Medicine, University of East Anglia,
Norfolk, UK
7Tri-State Pulmonary Associates, Cincinnati, Ohio
8Edinburgh Delirium Research Group, Geriatric Medicine, Division of Health Sciences and Centre
for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
Abstract
BACKGROUND—Despite the significant burden of delirium among hospitalized adults, critical
appraisal of systematic data on delirium diagnosis, pathophysiology, treatment, prevention, and
outcomes is lacking.
PURPOSE—To provide evidence-based recommendations for delirium care to practitioners, and
identify gaps in delirium research.
DATA SOURCES—Medline, PubMed, the Cochrane Library, and the Cumulative Index to
Nursing and Allied Health Literature (CINAHL) information systems fromJanuary 1966 to April
2011.
STUDY SELECTION—All published systematic evidence reviews (SERs) on delirium were
evaluated.
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DATA EXTRACTION—Three reviewers independently extracted the data regarding delirium
risk factors, diagnosis, prevention, treatment, and outcomes, and critically appraised each SER as
good, fair, or poor using the United States Preventive Services Task Force criteria.
DATA SYNTHESIS—Twenty-two SERs graded as good or fair provided the data. Age,
cognitive impairment, depression, anticholinergic drugs, and lorazepam use were associated with
an increased risk for developing delirium. The Confusion Assessment Method (CAM) is reliable
for delirium diagnosis outside of the intensive care unit. Multicomponent nonpharmacological
interventions are effective in reducing delirium incidence in elderly medical patients. Low-dose
haloperidol has similar efficacy as atypical antipsychotics for treating delirium. Delirium is
associated with poor outcomes independent of age, severity of illness, or dementia.
CONCLUSION—Delirium is an acute, preventable medical condition with short- and long-term
negative effects on a patient’s cognitive and functional states.
Delirium is a syndrome of disturbance of consciousness, with reduced ability to focus,
sustain, or shift attention, that occurs over a short period of time and fluctuates over the
course of the day.1 It encompasses a variety of cognitive, behavioral, and psychological
symptoms including inattention, short-term memory loss, sleep disturbances, agitated
behaviors, delusions, and visual hallucinations.2 Delirium complicates the care of 70% to
80% of mechanically ventilated patients in intensive care units (ICUs).3 Of 13 million
patients aged 65 and older hospitalized in 2002, 10% to 52% had delirium at some point
during their admission.4,5
Patients experiencing delirium have a higher probability of death during their hospital stay,
adjusted for age, gender, race, and comorbidities.3,6,7 They are more vulnerable to hospital-
acquired complications leading to prolonged ICU and hospital stay, new institutionalization,
and higher healthcare costs.3,6,7 Even with such a range of poor outcomes, the rates of
delirium recognition are low,8 resulting in inadequate management.9 There has been
considerable growth in the number of articles published on delirium in recent years.
Therefore, it is of value to provide a state-of-the-art summary of robust evidence in the field
to healthcare personnel and delirium investigators.
We systematically reviewed the literature to identify published systematic evidence reviews
(SERs), which evaluated the evidence on delirium risk factors, diagnosis, pathogenesis,
prevention, treatment, and outcomes. We then summarized the data from the
methodologically sound SERs to provide the reader with a clinically oriented summary of
delirium literature for patient care. We also identify current gaps in delirium literature, and
present future directions for delirium investigators to design studies that will enhance
delirium care.
DATA SOURCES AND REVIEW METHODS
The domains of risk factors, diagnosis, pathophysiology, prevention, treatment, and
outcomes were selected a priori to capture all relevant SERs regarding delirium based on the
framework suggested by the American Delirium Society task force.10 To maximize article
retrieval, a 3-step search strategy was applied. First, we searched the electronic database
utilizing OVID Medline, PubMed, the Cochrane Library, and Cumulative Index of Nursing
and Allied Health Literature (CINAHL) using the following delirium-specific search terms:
delirium, confusion, agitation, mental status change, inattention, encephalopathy, organic
mental disorders, and disorientation. We combined the above terms with the following study
design terms: technical report, systematic evidence review, systematic review, meta-
analysis, editorial, and clinical reviews. We limited our search to human subjects. We
excluded studies that: a) enrolled patients aged <18; b) enrolled patients with current or past
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Diagnostic and Statistical Manual of Mental Disorders (DSM) Axis I psychotic disorders; c)
did not have standardized delirium evaluation; d) evaluated alcohol or substance abuse-
related delirium; e) did not use a systematic search method for identifying delirium-related
articles; and f) evaluated delirium sub-types. We searched articles published from January
1966 through April 2011. Second, a manual search of references of the retrieved papers plus
an Internet search using Google Scholar was conducted to find additional SERs. Titles and
abstracts were screened by 2 reviewers (B.A.K., M.Z.). Authors of the included studies were
contacted as necessary. Third, a library professional at the Indiana University School of
Medicine independently performed a literature search, and those results were compared with
our search to retrieve any missing SERs.
The methodological quality of each SER was independently assessed by 2 reviewers
(B.A.K., M.Z.) using the United States Preventive Services Task Force (USPSTF) Critical
Appraisal for SER.11 This scale assesses parameters that are critical to the scientific
credibility of an SER and categorizes the SER as poor, fair, or good (Table 1). The 2
reviewers (B.A.K., M.Z.) used a data extraction form to record the following information
from each SER: primary author, publication year, number and type of studies, number of
participants and their mean age, study population, method for delirium diagnosis, risk
factors, preventive and therapeutic interventions, and outcomes. Any disagreement between
reviewers in SER selection, data extraction, or SER appraisal was resolved through
discussion with a third reviewer (M.A.B.). The conflicting findings among SERs were
resolved by consensus and by including the findings from a good SER over a fair SER.
RESULTS
Our search yielded 76,060 potential citations, out of which we identified 38 SERs meeting
our inclusion criteria (Table 2). Figure 1 outlines our search strategy. Based on the USPSTF
criteria, 22 SERs graded as good or fair provided the data to establish our review.
1: What Are the Risk Factors for Development of Delirium in Hospitalized Patients?
We found 6 SERs12–17 that evaluated risk factors for the development of delirium. Three
reviews included only surgical patients,12–14 1 focused on the intensive care unit (ICU),15
and the remaining 2 had both medical and surgical patients.16,17 Risk factors identified in an
elective vascular surgery population were age >64, preoperative cognitive impairment,
depression, intraoperative blood transfusions, and previous amputation. 12 The risk of
incident delirium conferred by general anesthesia compared to regional anesthesia in non-
cardiac surgery patients was not significantly different among both groups.13 One SER14
focused on the effects of different opioid analgesics on postoperative delirium, and whether
route of administration of medicines (intravenous vs epidural) had any impact on delirium.
Mepiridine was consistently associated with an increased risk of delirium in elderly surgical
patients, but there were no significant differences in postoperative delirium rates among
those receiving morphine, fentanyl, or hydromorphone. The rates of delirium did not differ
significantly between intravenous and epidural routes of analgesic administration, except in
one study where epidural route had more delirium cases, but in 85% of those cases,
mepiridine was used as an epidural agent. Risk factors explored in an ICU setting found
multiple predisposing and precipitating risk factors, with the surprising finding that age was
not a strong predictor of delirium.15 An association between delirium and drugs with
anticholinergic properties was found in 1 SER.16 There was no causal relationship between
structural or functional neuroimaging findings and delirium development.17
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2: What Is the Clinical Utility of Bedside Tools in Delirium Diagnosis?
The accuracy of bedside instruments in diagnosing delirium was assessed in an SER of 25
prospective studies. 18 Among the 11 scales reviewed, the Confusion Assessment Method
(CAM) had the most evidence supporting its use as a bedside tool (+likelihood ratio [LR],
9.6; 95% CI [confidence interval], 5.8–16.0; − LR, 0.16; 95% CI, 0.09–0.29). The Folstein
minimental status examination (MMSE)19 (score <24) was the least useful test for
identifying delirium (LR, 1.6; 95% CI, 1.2–2.0). Another SER evaluating the psychometric
properties of CAM demonstrated a sensitivity of 94% (CI, 91%–97%) and specificity of
89% (CI, 85%–94%).20 CAM also showed prognostic value with worsening of delirium
outcomes depending on the number of CAM items present.20
3: What Is the Underlying Pathophysiology of Delirium and Is There a Role of Measuring
Biomarkers for Delirium?
We found only 1 SER which examined the associations between cerebrospinal fluid
biomarkers and delirium.21 Delirium was associated with raised levels of serotonin
metabolites, interleukin-8, cortisol, lactate, and protein. Additionally, higher
acetylcholinesterase predicted poor outcome after delirium, and higher dopamine
metabolites were associated with psychotic features. Delirium was also associated with
reduced levels of somatostatin, β-endorphin, and neuron-specific enolase.
4: Can Delirium Be Prevented?
Nonpharmacologic Interventions—An SER22 reviewing multicomponent
interventions to prevent delirium identified 2 studies23,24 showing statistically significant
results. In the Yale Delirium Prevention Trial,23 the intervention was targeted toward
minimizing 6 risk factors in elderly patients (≥70 years of age) admitted to a general
medicine service, who did not have delirium at the time of admission, but were at risk for
delirium development. The interventions included: orientation activities for the cognitively
impaired, early mobilization, preventing sleep deprivation, minimizing the use of
psychoactive drugs, use of eyeglasses and hearing aids, and treating volume depletion. The
incidence of delirium was 9.9% with this intervention compared with 15% in the usual care
group (OR [odds ratio], 0.60; 95% CI, 0.39–0.92).23 The other studied patients with hip
fractures, randomized to either standard care versus the addition of a geriatrics consultation
preoperatively or immediately after hip repair, providing recommendations based on a
structured protocol.24 The incidence of delirium during hospitalization was 32% in the
geriatrics consultation group versus 50% in the standard care group (OR, 0.48; 95% CI,
0.23–0.98; relative risk [RR], 0.64; 95% CI, 0.37–0.98), but there was no difference in
duration of delirium.24
Pharmacologic Interventions—A Cochrane review found 6 randomized controlled
trials for preventing delirium in hospitalized surgical patients.25 Low-dose haloperidol
prophylaxis was found to be effective in reducing the severity (mean difference in delirium
rating scale score of 4.0 (95% CI, 2.0–5.8) and duration of delirium (RR, −6.44; 95% CI,
−7.64 to −5.24), along with shortening the length of hospital stay (mean difference in
hospital days, 5.5; 95% CI, 1.4–2.3) in hip surgery patients, but it did not prevent delirium
occurrence.26 A review by Campbell et al evaluated 9 studies testing pharmacological
interventions in preventing delirium in surgical patients.27 Use of a single-dose risperidone
after cardiac surgery decreased delirium incidence compared to placebo.28 Donepezil and
citicoline showed no benefit in preventing delirium.29–31 Early restoration of sleep cycles
with the use of a benzodiazepine/opiate combination and pain control with gabapentin
postoperatively reduced delirium incidence.32,33 Interventions started on day of surgery and
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continued for up to 3 days postoperatively were found to be effective in reducing delirium
incidence.27
5: How Should Delirium Be Treated?
Nonpharmacologic Interventions—The multicomponent intervention SER22
mentioned above evaluated the efficacy of interventions ranging from a geriatric psychiatric
consultation and a nursing liaison to assess patients’ daily pain management, to treating
hypoxemia and other metabolic derangements along with a standardized screening tool for
early detection of delirium. Delirious patients randomized to a geriatrician or a geriatric
psychiatrist’s consultation making treatment decisions, along with daily visits by a nursing
liaison, resulted in improvement in short portable mental status questionnaire scores
(SPMSQ) from 8.2 to 7.9, two weeks after admission, whereas the usual care group showed
a deterioration in scores (8.4 to 9.1).34 Though by week 8, the difference between both
groups disappeared. While the severity and recurrence rates of delirium were unchanged, the
trial by Inouye et al23 evaluating 6 standardized intervention protocols showed a significant
reduction in the total number of hospital days with delirium (105 vs 161 days, P = 0.02).
Training of nurses to use a delirium screening instrument to identify delirium in hip fracture
patients, along with prompt implementation of interventions based on a nursing guide for
evaluation of causes of delirium, resulted in a shorter duration of delirium (median = 1 day
vs 4 days, P = 0.03) and severity, compared to the usual care group.35 Daily assessment by a
gerontological nurse resulted in greater improvement in functional status (21% vs 10%).36
No difference in patients’ length of stay or mortality was demonstrated in any of the studies
included in the review.22 A Cochrane review assessing efficacy of multidisciplinary
interventions for reducing delirium in cognitively impaired patients did not identify any
studies.37
Pharmacologic Interventions—We identified 7 SERs,27,38–43 addressing the efficacy
and safety of various pharmacological interventions to treat delirium. Campbell et al
suggested that blocking the dopaminergic system with neuroleptics, and reducing the
exposure to lorazepam, might reduce delirium severity and duration among hospitalized
elders, including those in the ICU.27 There was no advantage of using atypical neuroleptics
over haloperidol. Low-dose haloperidol use was associated with reduced delirium severity
and duration in hip surgery patients.26 Seitz et al38 evaluated the efficacy and safety of
antipsychotics (haloperidol, olanzapine, quetiapine, risperidone, mianserin, and lorazepam)
in treating delirium symptoms. They evaluated prospective single-agent and comparison
trials. None of the studies included a placebo group. An improvement in delirium severity
was observed in the majority of studies, but there was no advantage of one agent over the
other in comparison trials. Most trials were underpowered to detect a clinically significant
difference and are of short duration (<7 days) to adequately assess for delirium resolution.
A Cochrane review39 comparing the efficacy of haloperidol over risperidone and olanzapine
for treating delirium showed similar findings as Campbell and colleagues’ SER.27 The
decrease in delirium severity scores was not significantly different using low-dose
haloperidol (<3.0 mg per day) compared with olanzapine and risperidone (OR, 0.63; 95%
CI, 0.29–1.38; P = 0.25). High-dose haloperidol (>4.5 mg per day) was associated with an
increased incidence of extrapyramidal adverse effects. The role of drug therapy for delirium
in terminally ill adult patients was evaluated in a Cochrane review40 and by Weber et al.41
They suggested the use of haloperidol or chlorpromazine in reducing delirium in acquired
immune deficiency syndrome (AIDS) patients. Benzodiazepines were ineffective for
treatment of non-alcohol withdrawal delirium. 42 In mechanically ventilated ICU patients,
dexmedetomidine treatment increased number of delirium/coma-free days compared with
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lorazepam (7 vs 3 days, P = 0.01).42 Cholinesterase inhibitor donepezil did not decrease
duration of delirium compared to placebo in postoperative orthopedic patients.43
6: What Is the Impact of Delirium on Patient Outcomes?
We found 4 SERs.44–47 Persistent delirium defined as delirium present on admission and at
the time of discharge or beyond, and its impact on outcomes in older hospitalized patients,
was evaluated in 1 SER. The combined proportions of patients with persistent delirium at
discharge, 1, 3, and 6 months were 44.7%, 32.8%, 25.6%, and 21%, respectively.44
Evaluation of prognosis was complicated by small number of subjects and differences in
length of follow up.
Delirium in elderly (>65 years) patients was associated with an increased risk of death45,46
compared with controls, with a mortality rate of 38% in delirious patients compared to
27.5% in controls (hazard ratio[HR], 1.95; 95% CI, 1.51–2.52).45 This association persisted
independent of preexisting dementia. Patients with delirium compared to controls were also
at increased risk of institutionalization (33.4% vs 10.7%) (OR, 2.41; 95% CI, 1.77–3.29) and
dementia (62.5% vs 8.1%) (OR, 12.52; 95% CI, 1.86– 84.21).45 In patients with dementia,
delirium increased the risk of 30-day rehospitalization and admission to long-term care,
compared to patients with dementia or delirium alone.47
DISCUSSION AND CLINICAL IMPLICATIONS
Our study identified age, cognitive impairment, depression, and mepiridine use for analgesia
as risk factors for delirium in surgical patients. Drugs with anticholinergic properties were
implicated in delirium development in both medical and surgical patients. The CAM has the
best available data to be used as a diagnostic tool for delirium. Multicomponent
interventions to prevent delirium occurrence are effective in a non-cognitively impaired
population, and low-dose haloperidol prophylaxis decreases delirium duration and severity
without affecting delirium incidence in hip surgery patients. There is no advantage of using
atypical antipsychotics over haloperidol in treating delirium, and low-dose haloperidol is as
effective as a higher dose without unwarranted extrapyramidal side effects. Delirium carries
a poor prognosis with an increased risk of death, institutionalization, and dementia.
Hospitals may benefit from implementing multicomponent strategies, focusing on at-risk
elderly medical and surgical patients, administered by a multidisciplinary team to reduce
delirium incidence. For ICU physicians and administrators, development of sedation
guidelines minimizing the use of benzodiazepines will decrease the risk of delirium
development.
A structured approach in diagnosing delirium is required to maximize identification. Use of
the CAM, based on best available data is recommended. However, the length of time in
doing the CAM (more than 10 minutes with the requisite mental status examination) and
insensitivity in nonexpert hands suggest a need for alternative screening tools. Haloperidol
should be the preferred first-line pharmacological therapy for delirium, with atypical
antipsychotics reserved for patients with contraindications to haloperidol or those who are
refractory to therapy with haloperidol. Figure 2 delineates a clinical model for delirium
management derived from the findings in the Results section.
FUTURE RESEARCH DIRECTIONS
We identified multiple areas without clear guidelines that could provide opportunities for
future research. A role for routine delirium screening can be clarified through a well-
designed delirium screening trial investigating the benefits of delirium screening, coupled
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with a multicomponent intervention versus usual care. Use of pharmacotherapy in delirium
prevention needs to be explored further in a large randomized trial, with 3 arms to compare
typical antipsychotics, atypical antipsychotics, and placebo in patients at risk for delirium
with a primary outcome of delirium incidence. In regard to delirium treatment, a large
randomized trial to compare haloperidol with atypical antipsychotics, with a placebo arm
focusing not only on delirium duration and severity, but also on long-term outcomes such as
rehospitalizations, institutionalization, cognitive impairment, and mortality, is warranted.
Figure 3 points out potential areas for researchers to investigate hypotheses generated by our
review and thereby improve delirium care.
To our knowledge, our SER presents the first summary of SERs in delirium. Prior to this
review, Michaud et al9 and National Institute for Health and Clinical Excellence48 published
delirium guidelines, but in both of these guidelines, evidence was collected from a multitude
of studies ranging in methodology from scientific review and meta-analysis to observational
studies, and the majority of recommendations were based on expert opinion. On the
contrary, our review was limited to rigorously conducted SERs; hence, we utilized the
highest level, critically appraised evidence to provide guidance to clinicians and researchers.
Limitations include a diverse group of studies with a heterogeneous population of patients,
preventing pooling of results. We did not review each individual study included in the 38
SERs. We excluded non-English language SERs, studies evaluating delirium subtypes,
alcohol or substance abuse-related delirium, or delirium associated with psychiatric
disorders. As we only reviewed SERs, some notable studies not included in the SERs may
have been missed.
CONCLUSION
Delirium among hospitalized patients is a common syndrome with a significant burden to
the healthcare system and society. The field of delirium has seen considerable advances in
diagnosis, prevention, and treatment over the last decade. Even with this advancement, there
are still areas of uncertainty, such as: the benefits and costs of delirium screening; the
benefits and harms of single or combined pharmacological agents for delirium prevention
and treatment; the development of a set of reliable biomarkers for delirium diagnosis,
prognosis, and response to therapy; the long-term effect of delirium-specific therapeutics on
patients’ cognitive, physical, and psychological functions; and the relationship between
delirium and the development of Alzheimer’s disease. As our understanding of delirium’s
impact on patients and healthcare improves, delirium should be identified as an indicator of
poor long-term prognosis, and should prompt immediate and effective evidence-based
management strategies, like any other critical illness.
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FIG. 1.
Presentation of the bibliographic search.
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FIG. 2.
Clinical model delineating delirium risk assessment, diagnosis, prevention, treatment, and
outcomes.
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FIG. 3.
Potential areas for future delirium research. Abbreviations: APO-E, apolipoprotein E; FDA,
US Food and Drug Administration.
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TABLE 1
United States Preventive Services Task Force Critical Appraisal Scale for Systematic Evidence Reviews
Criteria Rating Definition
Recent, relevant review with comprehensive sources and search strategies Good: If all the criteria are met
Explicit and relevant selection criteria
Standard appraisal of included studies
Valid conclusion
Recent, relevant review that is not clearly biased but lacks comprehensive sources and search
strategies
Fair: If this criterion is met
Outdated, irrelevant, or biased review Poor: If one or more of the criteria are met
There is no systematic search for studies
There are no explicit selection criteria
There is no standard appraisal of studies
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